Display options
Cite
Delnavaz Shahr A, Nasuhi Pur F. Calixmexitil: Calixarene-based Cluster of Mexiletine with Amplified Anti-myotonic Activity as A Novel Use-dependent Sodium Channel Blocker. Iran J Pharm Res. 2019;18(3):1351-1357doi: 10.22037/ijpr.2019.1100768.
Delnavaz Shahr, A., & Nasuhi Pur, F. (2019). Calixmexitil: Calixarene-based Cluster of Mexiletine with Amplified Anti-myotonic Activity as A Novel Use-dependent Sodium Channel Blocker. Iranian journal of pharmaceutical research : IJPR, 18(3), 1351-1357. https://doi.org/10.22037/ijpr.2019.1100768
Delnavaz Shahr, Amirali, and Nasuhi Pur, Fazel. "Calixmexitil: Calixarene-based Cluster of Mexiletine with Amplified Anti-myotonic Activity as A Novel Use-dependent Sodium Channel Blocker." Iranian journal of pharmaceutical research : IJPR vol. 18,3 (2019): 1351-1357. doi: https://doi.org/10.22037/ijpr.2019.1100768
Delnavaz Shahr A, Nasuhi Pur F. Calixmexitil: Calixarene-based Cluster of Mexiletine with Amplified Anti-myotonic Activity as A Novel Use-dependent Sodium Channel Blocker. Iran J Pharm Res. 2019;18(3):1351-1357. doi: 10.22037/ijpr.2019.1100768. PMID: 32641945; PMCID: PMC6934949.
Copy Download .nbib Format: NLM
Share it on

Iran J Pharm Res. 2019;18(3):1351-1357. doi: 10.22037/ijpr.2019.1100768.

Calixmexitil: Calixarene-based Cluster of Mexiletine with Amplified Anti-myotonic Activity as A Novel Use-dependent Sodium Channel Blocker.

Iranian journal of pharmaceutical research : IJPR

Amirali Delnavaz Shahr, Fazel Nasuhi Pur

Affiliations

  1. Department of Chemistry, Faculty of Science, Urmia University, Urmia, Iran.
  2. Health Technology Incubator Center, Urmia University of Medical Sciences, Urmia, Iran.

PMID: 32641945 PMCID: PMC6934949 DOI: 10.22037/ijpr.2019.1100768

Abstract

Mexiletine as the first choice drug in myotonia treatment is a chiral sodium channel blocker clinically used in its racemic form. The phenolic structure of this drug, prompted us to design its novel calix[4]arene-based cluster in a chalice-shaped structure. Therefore, the present study reports the synthesis and

Keywords: Amplify; Antimyotonic activity; Calixarene; Cluster; Mexiletine; Sodium channel blocker

References

  1. Eur J Pain. 1998 Mar;2(1):3-14 - PubMed
  2. Pharmacotherapy. 1986 Jan-Feb;6(1):1-9 - PubMed
  3. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;352(6):653-61 - PubMed
  4. Physiol Rev. 1985 Apr;65(2):310-56 - PubMed
  5. Iran J Pharm Res. 2015 Fall;14(4):1181-7 - PubMed
  6. J Health Econ. 2003 Mar;22(2):151-85 - PubMed
  7. Neuropharmacology. 2017 Feb;113(Pt A):206-216 - PubMed
  8. Clin Pharmacokinet. 1999 Nov;37(5):361-84 - PubMed
  9. Mol Divers. 2016 Aug;20(3):781-7 - PubMed
  10. Am Heart J. 1984 May;107(5 Pt 2):1058-65 - PubMed
  11. J Gen Physiol. 1976 Mar;67(3):265-93 - PubMed
  12. Iran J Pharm Res. 2019 Winter;18(1):30-33 - PubMed
  13. J Med Chem. 2003 Nov 20;46(24):5238-48 - PubMed

Publication Types